HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
June 29, 2021 08:00 ET
|
HiberCell
NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
June 10, 2021 08:00 ET
|
HiberCell
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...
HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital
May 19, 2021 08:00 ET
|
HiberCell
Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company...